Hemostemix (CVE:HEM) Stock Price Down 16.7% – Time to Sell?

Hemostemix Inc. (CVE:HEM) shares were down 16.7% during trading on Friday . The stock traded as low as C$0.08 and last traded at C$0.08. Approximately 405,500 shares changed hands during trading, an increase of 4% from the average daily volume of 389,087 shares. The stock had previously closed at C$0.09.

Hemostemix Price Performance

The stock has a market capitalization of C$11.66 million, a price-to-earnings ratio of -2.33 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The company has a 50 day moving average of C$0.12 and a 200 day moving average of C$0.13.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.